# Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants

> **NCT00425737** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 405 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Rotarix

## Key facts

- **NCT ID:** NCT00425737
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2001-07
- **Final completion:** 2001-07
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425737, "Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00425737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*